Shafeek Buhlak
Research Subjects
Shafeek Buhlak has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Nadeem Abad
3 shared publicationsAdil Mardinoglu
Royal Institute of Technology (KTH) - Science for Life Laboratory (SciLife Lab)
2 shared publicationsEl Mokhtar Essassi
2 shared publications- Essam Hanashalshahaby
Trustlife Labs, Drug Research & Development Center, Istanbul 34774, Turkey
2 shared publications Hasan Turkez
Atatürk University - Department of Medical Biology
2 shared publicationsJihane Akachar
2 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by European Journal of Chemistry in European Journal of Chemistry
- Vol. 16 (4) , 356-363
Enzyme-catalyzed kinetic resolution of spirocyclic secondary amines obtained by ring-closing metathesis, as well as synthesis of cyclopentane[c]pyrrole and -pyridines by the Pauson-Khand reaction
As herein defined; a ring closing metathesis (RCM) reaction of N-anchored homoallylic dienes followed by enzymatic kinetic resolution and ring closing enyne metathesis (RCEM) with an intramolecular Pauson-Khand reaction of N-tethered homopropargylic enynes are described for the first time. RCM afforded azaspirodeca and -undecadiene with 78 and 82% chemical yields, as well as azaspironona and decadienecarboxylates with 65 and 70% chemical yields, respectively. Furthermore, RCEM protocol resulted in conjugated diene 50% chemical yield. Moreover, intramolecular Pauson-Khand reaction is also applied to enynes, which yielded cyclopenta[c]pyrrole-carboxylate as diastereomeric mixtures; besides cyclopenta[c]pyridin-one and cyclopenta[c]pyridin-carboxylate frameworks as single diastereomers. Above all, secondary amines (azaspirodeca and undecadiene) have been efficiently resolved through an enzyme-catalyzed reaction in a moderate ee up to 77 and 20% ee, with their corresponding esters up to 75 and 55% ee, in the presence of CAL-B (being the most effective biocatalyst) and recombinant from Aspergillus oryzae. Both CAL-B and CAL-A-CLEA afforded reverse enantiomeric separation of them for the first time.
- 31 December 2025
- Published by European Journal of Chemistry in European Journal of Chemistry
- Vol. 16 (4) , 356-363
Open AccessEnzyme-catalyzed kinetic resolution of spirocyclic secondary amines obtained by ring-closing metathesis, as well as synthesis of cyclopentane[c]pyrrole and -pyridines by the Pauson-Khand reaction
As herein defined; a ring closing metathesis (RCM) reaction of N-anchored homoallylic dienes followed by enzymatic kinetic resolution and ring closing enyne metathesis (RCEM) with an intramolecular Pauson-Khand reaction of N-tethered homopropargylic enynes are described for the first time. RCM afforded azaspirodeca and -undecadiene with 78 and 82% chemical yields, as well as azaspironona and decadienecarboxylates with 65 and 70% chemical yields, respectively. Furthermore, RCEM protocol resulted in conjugated diene 50% chemical yield. Moreover, intramolecular Pauson-Khand reaction is also applied to enynes, which yielded cyclopenta[c]pyrrole-carboxylate as diastereomeric mixtures; besides cyclopenta[c]pyridin-one and cyclopenta[c]pyridin-carboxylate frameworks as single diastereomers. Above all, secondary amines (azaspirodeca and undecadiene) have been efficiently resolved through an enzyme-catalyzed reaction in a moderate ee up to 77 and 20% ee, with their corresponding esters up to 75 and 55% ee, in the presence of CAL-B (being the most effective biocatalyst) and recombinant from Aspergillus oryzae. Both CAL-B and CAL-A-CLEA afforded reverse enantiomeric separation of them for the first time.
- Open Access
- 8 February 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 233
Design, Synthesis, and Computational Evaluation of 3,4-Dihydroquinolin-2(1H)-One Analogues as Potential VEGFR2 Inhibitors in Glioblastoma Multiforme
Background/Objectives: Glioblastoma multiforme (GBM), an aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment due to its resistance to current therapies and poor prognosis. This study aimed to synthesise and evaluate 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, designed to enhance druggability and solubility, and to investigate their potential as VEGFR2 inhibitors for GBM treatment. Methods: The synthesised compounds were analysed using in silico methods, including molecular docking and dynamics studies, to assess their interactions with key residues within the VEGFR2 binding pocket. In vitro evaluations were performed on U87-MG and U138-MG GBM cell lines using MTT assays to determine the IC50 values of the compounds. Results: Among the tested compounds, 4u (IC50 = 7.96 μM), 4t (IC50 = 10.48 μM), 4m (IC50 = 4.20 μM), and 4q (IC50 = 8.00 μM) demonstrated significant antiproliferative effects against both the U87-MG and U138-MG cell lines. These compounds exhibited markedly higher efficacy compared to temozolomide (TMZ), which showed IC50 values of 92.90 μM and 93.09 μM for U87-MG and U138-MG, respectively. Molecular docking and dynamics studies confirmed strong interactions between the compounds and VEGFR2 kinase, supporting their substantial anti-cancer activity. Conclusions: This study highlights the promising potential of 3,4-dihydroquinolin-2(1H)-one analogues, particularly 4m, 4q, 4t, and 4u, as VEGFR2-targeting therapeutic agents for GBM treatment. Further detailed research is warranted to validate and expand upon these findings.
- 8 February 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 233
Open AccessDesign, Synthesis, and Computational Evaluation of 3,4-Dihydroquinolin-2(1H)-One Analogues as Potential VEGFR2 Inhibitors in Glioblastoma Multiforme
Background/Objectives: Glioblastoma multiforme (GBM), an aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment due to its resistance to current therapies and poor prognosis. This study aimed to synthesise and evaluate 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, designed to enhance druggability and solubility, and to investigate their potential as VEGFR2 inhibitors for GBM treatment. Methods: The synthesised compounds were analysed using in silico methods, including molecular docking and dynamics studies, to assess their interactions with key residues within the VEGFR2 binding pocket. In vitro evaluations were performed on U87-MG and U138-MG GBM cell lines using MTT assays to determine the IC50 values of the compounds. Results: Among the tested compounds, 4u (IC50 = 7.96 μM), 4t (IC50 = 10.48 μM), 4m (IC50 = 4.20 μM), and 4q (IC50 = 8.00 μM) demonstrated significant antiproliferative effects against both the U87-MG and U138-MG cell lines. These compounds exhibited markedly higher efficacy compared to temozolomide (TMZ), which showed IC50 values of 92.90 μM and 93.09 μM for U87-MG and U138-MG, respectively. Molecular docking and dynamics studies confirmed strong interactions between the compounds and VEGFR2 kinase, supporting their substantial anti-cancer activity. Conclusions: This study highlights the promising potential of 3,4-dihydroquinolin-2(1H)-one analogues, particularly 4m, 4q, 4t, and 4u, as VEGFR2-targeting therapeutic agents for GBM treatment. Further detailed research is warranted to validate and expand upon these findings.
- Open Access
- 9 August 2024
- Published by Elsevier in SSRN Electronic Journal
Design, Synthesis and Evaluation of Novel 3,4-Dihydroquinolin-2(1h)-One Analogues as Vegfr2 Kinase Inhibitors Against Human Glioblastoma Multiforme
Glioblastoma multiforme (GBM), an exceptionally aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment. The rapid progression of GBM and the difficulty of achieving drug penetration through the blood-brain barrier (BBB) hinder current therapeutic approaches. This highlights the critical need for developing new and potent medications specifically targeting GBM. This study focuses on the synthesis of 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, integrating enhanced druggable features and solubilizing entities. In silico-analyses provided insight into the inhibitory effects of these compounds, highlighting interactions with essential residues within the target's VEGFR2 binding pocket. In vitro evaluations conducted on two different GBM cell lines (U87-MG) and (U138-MG), compounds 4u (IC50=7.96 µM), 4t (IC50=10.48 µM) and 4m (IC50=4.20 µM), 4q (IC50=8.00 µM) demonstrated significant efficacy, respectively. These analogues markedly reduced the viability of both U87-MG and U138-MG GBM cells compared with temozolomide (TMZ) (IC50=92.90 µM /U87-MG and 93.09 µM /U138-MG). Molecular docking studies and dynamics focusing on VEGFR2 Kinase, a key factor in GBM pathogenesis, showed that our 3,4-dihydroquinolin-2(1H)-one analogues possess substantial anti-cancer activity against GBM cells. Our results emphasize the notable anti-cancer potential of the novel 3,4-dihydroquinolin-2(1H)-one analogues, especially 4m, 4q, 4t, and 4u, against GBM. We advocate for further detailed research to confirm and investigate the therapeutic value of these promising compounds.
- 9 August 2024
- Published by Elsevier in SSRN Electronic Journal
Open AccessDesign, Synthesis and Evaluation of Novel 3,4-Dihydroquinolin-2(1h)-One Analogues as Vegfr2 Kinase Inhibitors Against Human Glioblastoma Multiforme
Glioblastoma multiforme (GBM), an exceptionally aggressive and deadly brain tumour, presents significant challenges in achieving effective treatment. The rapid progression of GBM and the difficulty of achieving drug penetration through the blood-brain barrier (BBB) hinder current therapeutic approaches. This highlights the critical need for developing new and potent medications specifically targeting GBM. This study focuses on the synthesis of 23 novel analogues of 3,4-dihydroquinolin-2(1H)-one, integrating enhanced druggable features and solubilizing entities. In silico-analyses provided insight into the inhibitory effects of these compounds, highlighting interactions with essential residues within the target's VEGFR2 binding pocket. In vitro evaluations conducted on two different GBM cell lines (U87-MG) and (U138-MG), compounds 4u (IC50=7.96 µM), 4t (IC50=10.48 µM) and 4m (IC50=4.20 µM), 4q (IC50=8.00 µM) demonstrated significant efficacy, respectively. These analogues markedly reduced the viability of both U87-MG and U138-MG GBM cells compared with temozolomide (TMZ) (IC50=92.90 µM /U87-MG and 93.09 µM /U138-MG). Molecular docking studies and dynamics focusing on VEGFR2 Kinase, a key factor in GBM pathogenesis, showed that our 3,4-dihydroquinolin-2(1H)-one analogues possess substantial anti-cancer activity against GBM cells. Our results emphasize the notable anti-cancer potential of the novel 3,4-dihydroquinolin-2(1H)-one analogues, especially 4m, 4q, 4t, and 4u, against GBM. We advocate for further detailed research to confirm and investigate the therapeutic value of these promising compounds.